Carbapenem‐resistant Serratia marcescens bloodstream infection in hematopoietic stem cell transplantation patients: Will it be the next challenge?. Issue 4 (18th May 2021)

• Record Type: Journal Article
• Authors: do Prado, Gladys V. B.; Mendes, Elisa T.; Martins, Roberta C. R.; Perdigão‐Neto, Lauro V.; Freire, Maristela P.; Spadão, Fernanda; de Castro Lima, Victor A. C.; Rossi, Flavia; Guimarães, Thais; Levin, Anna S.; Rocha, Vanderson; Costa, Silvia F.
• Is Part Of: Transplant infectious disease. Volume 23:Issue 4(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-18
• Subjects: bone marrow transplant -- carbapenem‐resistant Serratia -- hematopoietic stem cell transplantation -- KPC -- NDM -- Serratia marcescens; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.13630
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Surveillance programs have been reporting decreasing rates of carbapenem‐sensitivity in Serratia marcescens, leading to a concern regarding the few remaining therapeutic options to treat these multidrug‐resistant (MDR) organisms. Here, we describe a case series of 11 stem cell hematopoietic transplantation patients infected (N = 6) or colonized (N = 5) by carbapenem‐resistant S marcescens ( CrSm ) from 2010 to 2013. The comorbidities found were acute renal insufficiency (3/11), neutropenia (7/11), and mucositis (8/11), and the mortality rate was 64%. KPC was the most prevalent carbapenemase detected (8/11) and tigecycline and gentamicin were the antimicrobials used as treatment.